Dr. Christoph Tapprich

Shaped global lymphoma strategy, represented, the medical & clinical perspective ensuring regional needs in global decision-making. Aligned regional insights with late-stage development and lifecycle strategy by partnering closely with R&D teams, strengthening global pipeline strategy and regional execution. Bridged development and cross-functional stakeholders within a global matrix structure.

Served as Study Responsible Physician for a late-stage Phase 3 CAR-T program in multiple myeloma, providing medical oversight of trial conduct and contributing to delivery of key development milestones. Safeguarded patient safety and data quality by partnering with Global Clinical Development, Safety, and Clinical Operations, ensuring protocol adherence and high-quality data generation in a global trial setting. Supported benefit-risk evaluation by conducting medical safety evaluation of oncology-specific a

Led EMEA Medical Strategy and execution for B-cell malignancies as a core member of the Integrated Brand & Value Team, driving late-stage development involvement, evidence generation, and publication planning, embedding medical insights into a 10-year asset and indication strategy. Directed regional company-sponsored and investigator-initiated study governance, serving as company Study Responsible Physician for a pan-EMEA IIS portfolio of more than 40 studies,  ensuring scientific quality and alignment with

Supported development and execution of regional medical and clinical strategy across hematologic indications by partnering with cross-functional regional stakeholders. Established and managed the regional investigator-initiated study program, serving as company Study Responsible Physician for all contracted regional IIS, building a well-governed regional evidence-generation pipeline. Provided medical input into study design, investigator engagement, and scientific communication, including market research an

Served as Medical Lead for the local hematology portfolio, spanning multiple assets and rare diseases, driving pre-launch and early-launch clinical activities including pre-approval access programs. Acted as Study Responsible Physician for local investigator-initiated and company-sponsored non-interventional studies in multiple myeloma, generating regional real-world evidence to support disease and product strategy. Contributed medical and scientific expertise to HTA dossiers and oral hearings (G-BA) by par

Board Certification Internal Medicine 2008 Board Certification Hematology and Oncology 2010